June 1, 2021

Santhera & ReveraGen Announce Positive & Statistically Significant Topline Results in VISION-DMD Study

Santhera and ReveraGen today announced positive and statistically significant results from the 24-week readout of the VISION-DMD study of vamorolone in Duchenne. The companies report that study demonstrated strong efficacy across primary and secondary endpoints…

Learn More

April 28, 2021

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne

Today Santhera and ReveraGen shared 2.5-year treatment data with vamorolone in Duchenne. In the announcement below the companies reported on data from 46 patients who have participated in two open-label extension studies covering 2.5 years,…

Learn More

March 4, 2021

Santhera Announces Completion of First 6-Month Period of VISION-DMD Trial with Vamorolone in Duchenne

Santhera Pharmaceuticals has reached an important milestone in the VISION-DMD study of vamorolone in people with Duchenne, conducted by partner ReveraGen Biopharma Inc. The company today announced that it has completed the last visit of…

Learn More

February 1, 2021

Santhera Shares Community Update on Phase 2b Trial for Vamorolone

Santhera Pharmaceuticals has shared an update with the community regarding the phase 2b trial for vamorolone, which the company expects to have data from in the second quarter of 2021. The update includes contact information…

Learn More

November 17, 2020

ReveraGen Receives $3.3 Million NIH Grant for NDA Preparations for Vamorolone in Duchenne

The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded a $3.3 million grant to ReveraGen Inc. to support the advancement of vamorolone towards FDA submission and…

Learn More

September 23, 2020

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Santhera announced a new publication in the journal PLOS Medicine describing new open-label, long-term clinical data on the safety, tolerability and efficacy…

Learn More

September 11, 2020

Santhera Announces Full Enrollment of ReveraGen’s VISION-DMD Study with Vamorolone in Duchenne

Santhera announced that ReveraGen’s VISION-DMD study for vamorolone in Duchenne has completed enrollment. Subject to a positive study outcome, this could allow for a regulatory submission to the FDA in the fourth quarter of 2021….

Learn More

September 2, 2020

Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne and All Other Indications

We congratulate Santhera as they have exercised the option to obtain worldwide rights to vamorolone in Duchenne and all other indications. The license gives Santhera worldwide rights to vamorolone which means Santhera is responsible for…

Learn More

June 2, 2020

Santhera Announces Completion of ReveraGen’s Long-Term Extension Study with Vamorolone in Duchenne

PPMD is excited to learn that Santhera Pharmaceuticals and partner ReveraGen Biopharma Inc. have completed a long-term, open-label extension study of 24 months duration with vamorolone in patients with Duchenne. Data from this study in…

Learn More

May 28, 2020

ReveraGen to Share Individual Patient Results with Trial Participants

ReveraGen has provided a letter to participants in their vamorolone trial indicating promising results with strength and mobility of patients on drug. Additionally, thanks to a NIH grant, ReveraGen will be sharing individual results with…

Learn More